ClinicalTrials.gg
CompletedNCT01749137Updated Aug 14, 2023Results posted

Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants

A Phase 2 interventional study of Setmelanotide and Placebo in Overweight, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,479 studies in Overweight with a site in United States — 273 open to participants now, 400 under way, 69 of them phase 3. Overweight · United States.

Enrollment
742nd of 1,365
74 · median 85
Started
2013
with 36 others
Phase 2
147 of 1,479
29 open now
Registered
334th of 1,479
by date

Among the 1,479 studies in Overweight with a site in United States, this one is the 742nd largest by enrollment of the 1,365 interventional ones that give a count, is one of 37 that started in 2013, is one of 147 in phase 2, and was the 334th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

273 of the 1,479 studies in Overweight with a site in United States are open now. Recruiting first, the newest first:

268 more — sign in →

All 273 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,479 studies in Overweight with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of RM-493 on mean percent body weight loss, and other weight loss parameters as well as Pharmacokinetic (PK) profile, and ambulatory blood pressure in obese participants. The study is designed to evaluate the efficacy and tolerability of a single dose of RM-493. The study drug (RM-493 and placebo) will be administered subcutaneously in a blinded fashion.

03

Conditions studied

  • Overweight

Browse trials for

Keywords

  • Overweight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be between the age of 18 and 65.
  2. Able to provide voluntary, written with comprehension of all aspects of the protocol, prior to any study procedures.
  3. In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities.
  4. : 35-50 Kg/m\^2, inclusive. It is planned that approximately 20 (but no more than 50% of the total participants enrolled) of these participants will have a BMI ≥ 40 Kg/m\^2
  5. Stable body weight (+/- 5 Kg) during previous 6 months.
  6. Blood pressure (\<150/95 mmHg); may include stable dose (≥ 30 days of use) of up to two anti-hypertensive medications to achieve control that are intended to remain on a stable dose during the protocol.
  7. Willingness and demonstrates ability to self-administer study medication subcutaneously via an infusion pump during the placebo practice period.
  8. Willing to maintain a healthy diet and exercise regime throughout study as recommended by counseling at study start.
  9. Females of must agree to be abstinent or else use any two of the following medically acceptable forms of from the Screening Period through the completion of study treatment: hormonal, condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or intrauterine device (IUD). Hormonal contraception must have started at least 3 months prior to screening. A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception. Participants must agree to practice the above birth control methods for 30 days after completion of study treatment as a safety precaution.
  10. Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or for at least 12 months (and confirmed with a screening follicle stimulating hormone (FSH) level in the post-menopausal range), do not require contraception during the study.
  11. Males with female partners of childbearing potential must agree to use two medically acceptable forms of contraception as described above, with one of the two forms being condom with spermicide, from the Screening Period through 90 days after completion of study treatment. Males with female partners of childbearing potential who themselves are surgically sterile (status post vasectomy) must agree to use condoms with spermicide over the same period of time.

Exclusion criteria

Exclusion Criteria:

  1. Fasting blood glucose > than 140 mg/dL.
  2. (HbA1c) ≥6.5%.
  3. Thyroid stimulating hormone (TSH) level outside the normal range.
  4. Creatinine > 1.5 times the .
  5. Liver function tests > 2 times the upper limit of normal.
  6. Active or history of any significant medical condition including renal, hepatic, pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic, metabolic, neurologic or hematological disease.
  7. Participants with a history of the following:

    1. Uncontrolled hypertension;
    2. Diabetes requiring medical treatment, presently or in the past;
    3. Major depressive disorder within the last 2 years;
    4. Any lifetime history of a suicide attempt;
    5. Any suicidal behavior in the last month;
    6. Other severe psychiatric disorders (e.g. schizophrenia, bipolar disorder, severe eating disorders including bulimia).
  8. A patient health questionnaire - 9 (PHQ-9) score of ≥15.
  9. Any suicidal ideation of type 4 or 5 on the columbia suicide severity rating scale (C-SSRS).
  10. Prior bariatric surgery.
  11. Treated with anorectic agents or drugs with anorexia as a frequent side event.
  12. Taking 3 or more anti-hypertensive medications.
  13. Acute illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the participant or obscure interpretation of laboratory test results or interpretation of study data.
  14. History of (HIV) infection.
  15. History of significant drug or anaphylaxis.
  16. History of hypersensitivity to proteins (e.g., allergy shots).
  17. Any abnormalities on screening laboratories as determined by the Investigator.
  18. Abnormal 12-lead (ECG) at screening or pre-dose (Day 1), except minor deviations deemed to be of no clinical significance by the Investigator. must be \< 450 ms.
  19. Received any experimental drugs or devices or have participated in a clinical study within 30 days prior to dosing.
  20. Hospitalization for surgery within the 3 months prior to screening except for minor outpatient procedures, or any planned hospitalizations during the study period.
  21. Poor venous access or inability to tolerate venipuncture.
  22. Inability to attend all study visits or comply with protocol requirements including fasting and restrictions on concomitant medication intake.
  23. Participation in weight loss programs during the study period, including nutritional supplements/ replacements other than as recommended by nutritional counseling provided at study start.
  24. Use of prescription medications on a regular basis with the following exceptions:

    1. (must be on for ≥3 months);
    2. Hormone replacement therapy (must be on stable dose for ≥3 months);
    3. Antihypertensives (\<3 medications on a stable dose for ≥ 30 days);
    4. Statins (dose must be ≤ half the maximum dose; must be on a stable dose ≥3 months);
    5. Fibrates (must be on stable dose for ≥3 months);
    6. Niacin (must be on stable dose for ≥3 months);
    7. Thyroxin (stable dose for ≥ 30 days);
    8. The last use of any other prescription medication must have been greater than 5 half-lives for the specific medication or at least 14 days prior to randomization, whichever is longer.
  25. Women who are pregnant or are breast feeding.
  26. Previously randomized and dosed in this study or previously exposed to RM-493.
  27. History of alcohol or drug abuse within 5 years of Screening Visit.
  28. Any other reason, which in the opinion of the Investigator would confound proper evaluation of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Setmelanotide

    Participants received 1 milligram (mg) setmelanotide every day by continuous subcutaneous infusion using the Omnipod insulin pump for a duration of 90 days.

    Drug: Setmelanotide

  • Placebo comparator
    Placebo

    Participants received placebo matching setmelanotide every day by continuous subcutaneous infusion using the Omnipod insulin pump for a duration of 90 days.

    Drug: Placebo

Interventions

  • Daily subcutaneous infusion

    Also known as: RM-493

  • DrugPlacebo

    Daily subcutaneous infusion

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight

    The mean percent change from baseline in body weight at Day 90 was analyzed.

    Time frame: Baseline and Day 90

Secondary outcomes

  1. Change From Baseline in Body Weight

    The mean change from baseline in body weight at day 90 was analyzed.

    Time frame: Baseline and Day 90

  2. Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight

    The percentage of participants who lost ≥ 5% of their baseline body weight was analyzed. 95% confidence interval is calculated based on Clopper-Pearson.

    Time frame: Baseline up to Day 90

  3. Number of Participants Who Consistently Achieved Targeted Plasma Concentration of ~6 Nanogram Per Milliliter (ng/mL)

    Number of Participants Who Consistently Achieved Targeted Plasma Concentration of \~6 ng/mL were reported.

    Time frame: Day 1: pre-dose and 2-hours post-infusion, Day 7, 14, 28, 56, and 90

  4. Percentage of Participants With Treatment Emergent Adverse Events

    An adverse event (AE) was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An adverse event (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. A treatment-emergent AE was defined as an AE with an onset date on or after day 1.

    Time frame: From first dose of study drug (Day 1) until end of study (Up to 184 days)

  5. Change From Baseline in Ambulatory Blood Pressure Monitoring Parameter (ABPM) - Systolic Blood Pressure

    Summary of individual average data at daytime, nighttime and 24 hours was reported.

    Time frame: Baseline and Day 28

  6. Change From Baseline in ABPM - Diastolic Blood Pressure

    Summary of individual average data at daytime, nighttime and 24 hours was reported.

    Time frame: Baseline and Day 28

  7. Change From Baseline in ABPM - Mean Arterial Blood Pressure

    Summary of individual average data at daytime, nighttime and 24 hours was reported.

    Time frame: Baseline and Day 28

  8. Change From Baseline in ABPM - Heart Rate

    Summary of individual average data at daytime, nighttime and 24 hours was reported.

    Time frame: Baseline and Day 28

  9. Change From Baseline in ABPM - Pulse Pressure

    Summary of individual average data at daytime, nighttime and 24 hours was reported.

    Time frame: Baseline and Day 28

  10. Percent Change From Baseline in Body Weight in Severely Obese Participants

    The mean percent change from baseline in body weight in severely obese participants at Day 90 was analyzed.

    Time frame: Baseline and Day 90

  11. Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight in Severely Obese Participants

    The percentage of participants who lost ≥ 5% of their baseline body weight loss in severely obese participants was analyzed. 95% confidence interval is calculated based on Clopper-Pearson confidence interval.

    Time frame: Baseline up to Day 90

07

Results

Posted Aug 14, 2023

Participant flow

Participant flow — Overall Study
MilestoneSetmelanotidePlacebo
Started3737
Completed2226
Not completed1511
Withdrew: Adverse event44
Withdrew: Lost to follow-up23
Withdrew: Physician decision10
Withdrew: Withdrawal by subject84

Outcome measures

PrimaryPercent Change From Baseline in Body Weight

The mean percent change from baseline in body weight at Day 90 was analyzed.

Time frame:
Baseline and Day 90
Reported as:
Mean · Percent change
Percent Change From Baseline in Body Weight
Percent changeSetmelanotidePlacebo
Percent Change From Baseline in Body Weight-2.0 ± 2.82-0.3 ± 2.96
Statistical analysis
  • Setmelanotide vs Placebo · Mixed Model Repeated Measures (MMRM) · p = 0.059 · Treatment difference: -1.1 · 95% CI -2.27 to 0.04
SecondaryChange From Baseline in Body Weight

The mean change from baseline in body weight at day 90 was analyzed.

Time frame:
Baseline and Day 90
Reported as:
Mean · Kilograms
Change From Baseline in Body Weight
KilogramsSetmelanotidePlacebo
Change From Baseline in Body Weight-2.2 ± 3.39-0.3 ± 3.34
Statistical analysis
  • Setmelanotide vs Placebo · MMRM · p = 0.079 · Treatment difference: -1.2 · 95% CI -2.48 to 0.14
SecondaryPercentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight

The percentage of participants who lost ≥ 5% of their baseline body weight was analyzed. 95% confidence interval is calculated based on Clopper-Pearson.

Time frame:
Baseline up to Day 90
Reported as:
Number · percentage of participants
Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight
percentage of participantsSetmelanotidePlacebo
Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight9.1 (1.9 to 24.3)5.6 (0.7 to 18.7)
Statistical analysis
  • Setmelanotide vs Placebo · Cochran-Mantel-Haenszel · p = 0.513 (P-values from a Cochran-Mantel-Haenszel (CMH) test, controlling for site and the stratification factor severely obese (yes/no).)
SecondaryNumber of Participants Who Consistently Achieved Targeted Plasma Concentration of ~6 Nanogram Per Milliliter (ng/mL)

Number of Participants Who Consistently Achieved Targeted Plasma Concentration of \~6 ng/mL were reported.

Time frame:
Day 1: pre-dose and 2-hours post-infusion, Day 7, 14, 28, 56, and 90
Reported as:
Count of participants · Participants
Number of Participants Who Consistently Achieved Targeted Plasma Concentration of ~6 Nanogram Per Milliliter (ng/mL)
ParticipantsSetmelanotide
Number of Participants Who Consistently Achieved Targeted Plasma Concentration of ~6 Nanogram Per Milliliter (ng/mL)8
SecondaryPercentage of Participants With Treatment Emergent Adverse Events

An adverse event (AE) was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An adverse event (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. A treatment-emergent AE was defined as an AE with an onset date on or after day 1.

Time frame:
From first dose of study drug (Day 1) until end of study (Up to 184 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events
percentage of participantsSetmelanotidePlacebo
Percentage of Participants With Treatment Emergent Adverse Events75.748.7
SecondaryChange From Baseline in Ambulatory Blood Pressure Monitoring Parameter (ABPM) - Systolic Blood Pressure

Summary of individual average data at daytime, nighttime and 24 hours was reported.

Time frame:
Baseline and Day 28
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Ambulatory Blood Pressure Monitoring Parameter (ABPM) - Systolic Blood Pressure
millimeter of mercury (mmHg)SetmelanotidePlacebo
Daytime individual average-2.45 ± 14.0711.83 ± 12.200
Night time individual average-3.26 ± 13.3101.24 ± 10.721
24 hour (hr) individual average-2.79 ± 13.1741.61 ± 11.165
SecondaryChange From Baseline in ABPM - Diastolic Blood Pressure

Summary of individual average data at daytime, nighttime and 24 hours was reported.

Time frame:
Baseline and Day 28
Reported as:
Mean · mmHg
Change From Baseline in ABPM - Diastolic Blood Pressure
mmHgSetmelanotidePlacebo
Daytime individual average-1.62 ± 9.6721.39 ± 5.591
Night time individual average-0.96 ± 9.5860.60 ± 5.184
24 hr individual average-1.38 ± 9.2611.09 ± 4.977
SecondaryChange From Baseline in ABPM - Mean Arterial Blood Pressure

Summary of individual average data at daytime, nighttime and 24 hours was reported.

Time frame:
Baseline and Day 28
Reported as:
Mean · mmHg
Change From Baseline in ABPM - Mean Arterial Blood Pressure
mmHgSetmelanotidePlacebo
Daytime individual average-1.27 ± 10.8861.70 ± 8.056
Night time individual average-2.15 ± 10.5890.86 ± 6.536
24 hr individual average-1.65 ± 10.2051.38 ± 7.018
SecondaryChange From Baseline in ABPM - Heart Rate

Summary of individual average data at daytime, nighttime and 24 hours was reported.

Time frame:
Baseline and Day 28
Reported as:
Mean · Beats per minute (BPM)
Change From Baseline in ABPM - Heart Rate
Beats per minute (BPM)SetmelanotidePlacebo
Daytime individual average1.44 ± 6.861-1.90 ± 8.702
Night time individual average-0.28 ± 8.2930.05 ± 10.420
24 hr individual average0.70 ± 6.703-1.07 ± 8.242
SecondaryChange From Baseline in ABPM - Pulse Pressure

Summary of individual average data at daytime, nighttime and 24 hours was reported.

Time frame:
Baseline and Day 28
Reported as:
Mean · mmHg
Change From Baseline in ABPM - Pulse Pressure
mmHgSetmelanotidePlacebo
Daytime individual average-0.83 ± 6.3200.44 ± 8.060
Night time individual average-2.30 ± 6.0380.65 ± 6.820
24 hr individual average-1.41 ± 5.6550.52 ± 7.366
SecondaryPercent Change From Baseline in Body Weight in Severely Obese Participants

The mean percent change from baseline in body weight in severely obese participants at Day 90 was analyzed.

Time frame:
Baseline and Day 90
Reported as:
Mean · Percent change
Percent Change From Baseline in Body Weight in Severely Obese Participants
Percent changeSetmelanotidePlacebo
Percent Change From Baseline in Body Weight in Severely Obese Participants-2.3 ± 3.34-0.7 ± 3.08
Statistical analysis
  • Setmelanotide vs Placebo · MMRM · p = 0.387 · Treatment difference: -0.8 · 95% CI -2.50 to 0.98
SecondaryPercentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight in Severely Obese Participants

The percentage of participants who lost ≥ 5% of their baseline body weight loss in severely obese participants was analyzed. 95% confidence interval is calculated based on Clopper-Pearson confidence interval.

Time frame:
Baseline up to Day 90
Reported as:
Number · percentage of participants
Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight in Severely Obese Participants
percentage of participantsSetmelanotidePlacebo
Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight in Severely Obese Participants11.8 (1.5 to 36.4)11.8 (1.5 to 36.4)
Statistical analysis
  • Setmelanotide vs Placebo · Cochran-Mantel-Haenszel · p = 1.000 (P-values from a Cochran-Mantel-Haenszel (CMH) test, controlling for site.)

Adverse events

Collected over From first dose of study drug (Day 1) until end of study (Up to 184 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Setmelanotide0/37 (0%)0/37 (0%)28/37 (75.7%)
Placebo0/37 (0%)1/37 (2.7%)18/37 (48.6%)
Most frequent serious events
Most frequent serious events
EventSetmelanotidePlacebo
Biliary dyskinesiaHepatobiliary disorders0/371/37
Most frequent other events
Showing 10 of 75
Most frequent other events
EventSetmelanotidePlacebo
Skin hyperpigmentationSkin and subcutaneous tissue disorders9/370/37
Upper respiratory tract infectionInfections and infestations3/375/37
Skin discolourationSkin and subcutaneous tissue disorders5/370/37
NauseaGastrointestinal disorders5/373/37
Application site pruritusGeneral disorders5/371/37
HeadacheNervous system disorders4/371/37
CellulitisInfections and infestations3/371/37
Decreased appetiteMetabolism and nutrition disorders3/370/37
Ear infectionInfections and infestations0/372/37
UrticariaSkin and subcutaneous tissue disorders2/370/37

Baseline characteristics

The Full Analysis Set (FAS) consisted of all randomized participants with both a baseline and at least one post-dose efficacy observation (for at least one efficacy endpoint).

Age, Continuous
Age, Continuous(years)SetmelanotidePlaceboTotal
Mean42.0 ± 9.7740.4 ± 11.7241.2 ± 10.74
Sex: Female, Male
Sex: Female, Male(Participants)SetmelanotidePlaceboTotal
Female313566
Male628
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SetmelanotidePlaceboTotal
Hispanic or Latino336
Not Hispanic or Latino343367
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SetmelanotidePlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American151631
White212142
More than one race000
Unknown or Not Reported101
Body Weight
Body Weight(Kilograms)SetmelanotidePlaceboTotal
Mean113.65 ± 16.074111.20 ± 10.031112.43 ± 13.362
08

Study locations

6 sites
  • Miami, Florida, United States
  • Lexington, Kentucky, United States
  • Rochester, New York, United States
  • Raleigh, North Carolina, United States
  • Dallas, Texas, United States
  • Renton, Washington, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Sep 2013, 8 months.

Results were first posted in Aug 2023, 9 years 10 months after primary completion. A results delay was requested in Nov 2014.

Of 102 industry-sponsored phase 2 interventional studies under Overweight, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 16. This study's 8 months is below that.

Counting every sponsor, half of 148 studies reached it within 13 months; a quarter within 8 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2012
First posted
Dec 13, 2012
StartActual
Jan 14, 2013
Primary completionActual
Sep 28, 2013
CompletionActual
Sep 28, 2013
Results delay requested
Nov 6, 2014
Results first posted
Aug 14, 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01749137
Responsible party
Sponsor
First posted
Dec 13, 2012
Start date
Jan 14, 2013
Primary completion
Sep 28, 2013
Completion
Sep 28, 2013
Results posted
Aug 14, 2023
Last update
Aug 14, 2023

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion